There are currently 492 clinical trials in Lexington, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kentucky, University of Kentucky/Markey Cancer Center, Saint Joseph Hospital East and Baptist Health Lexington. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: UK Markey Cancer Center, Lexington, Kentucky
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
NCT04892472
Recruiting
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to t... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
10/04/2023
Locations: Baptist Health Oncology Research, Lexington, Kentucky
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Precision Medicine Approach to Target Engagement for Emotion Regulation
NCT05651295
Recruiting
The proposed study is designed to first test whether teaching people personalized or standardized emotion regulation skills leads to greater decreases in daily negative emotion intensity. Second, using data from an initial sample, the investigators will prospectively assign an independent sample of participants to receive their predicted optimal or non-optimal skills to determine if it is feasible and efficacious to match participants to the most appropriate training condition. Results of these... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/29/2023
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Emotional Regulation, Depression, Anxiety, Borderline Personality Disorder, Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Eating Disorders
Register for Updates
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
NCT05586958
Recruiting
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
08/24/2023
Locations: Alliance for Multispecialty Research, LLC, Lexington, Kentucky
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
NCT05161429
Recruiting
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
Gender:
All
Ages:
30 years and above
Trial Updated:
06/16/2023
Locations: Humana, Lexington, Kentucky
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267
Recruiting
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Gender:
All
Ages:
Between 18 years and 81 years
Trial Updated:
04/14/2023
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: University of Kentucky A.B.Chandler Medical Center, Lexington, Kentucky
Conditions: Langerhans Cell Histiocytosis
Register for Updates
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
NCT02075775
Recruiting
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiogra... Read More
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
11/07/2022
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Register for Updates
Ketamine and Epigenetic Aging
NCT05294835
Recruiting
This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age laboratory test.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
09/07/2022
Locations: Wild Health, Lexington, Kentucky
Conditions: Depression, Post Traumatic Stress Disorder
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Kentucky Medical Center, Lexington, Kentucky
Conditions: Breast Cancer
Register for Updates
CSD201203: A Study to Determine Subject Puffing Patterns of a Non-cylindrical, Closed, Electronic Nicotine Delivery System at Three Nicotine Concentrations in an Ambulatory Setting
NCT05118139
Recruiting
This is a multi-center, open-label, parallel, three-study-group investigation to evaluate the puffing patterns of healthy adult consumers of tobacco products switching from a usual brand (UB) Electronic Nicotine Delivery Systems (ENDS) product to the ENDS Investigational Product (IP), over a 9-day ambulatory period.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/23/2022
Locations: AMR Lexington, Lexington, Kentucky
Conditions: Smoking, Tobacco Use, Electronic Cigarette Use
Register for Updates
Home OCT Fluid Visualization Agreement Study
NCT04907409
Recruiting
This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with s... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
03/08/2022
Locations: Retina Associates of Kentucky, Lexington, Kentucky
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates